- Cardone, C., Blauensteiner, B., Moreno-Viedma, V., Martini, G., Simeon, V., Vitiello, P. P., … Martinelli, E. (2020). AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. European Journal of Cancer, 138, 1-10. doi:10.1016/j.ejca.2020.07.010
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer
on 28 de setembre de 2020
with No hi ha comentaris
Deixa un comentari